Implantica Secures Over €1.2 Million for RefluxStop® Funding in Italy
In a significant move for the healthcare industry, Implantica AG, a pioneering medtech company, has recently announced substantial public tender wins in Italy. The company secured over €1.2 million in funding for its innovative RefluxStop® device, a groundbreaking solution aimed at treating gastroesophageal reflux disease (GERD), which affects approximately one billion people globally.
The funding was awarded through two multi-year public tender approvals at esteemed healthcare institutions: Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" in Palermo and the Ospedale di Brunico, part of the Azienda Sanitaria dell'Alto Adige in South Tyrol. This accomplishment marks a critical juncture for RefluxStop®, indicating its growing acceptance and recognition within Italy's national healthcare framework.
The RefluxStop® device is uniquely engineered to address the root causes of acid reflux without imposing pressure on the esophagus, unlike traditional surgical methods. Its innovative mechanism restores the natural position and function of the lower esophageal sphincter, which plays a crucial role in preventing acid from escaping the stomach. This is achieved without the encirclement and potential side effects associated with conventional reflux surgeries.
Italy is witnessing an uptick in the clinical deployment of this revolutionary treatment, with twelve Centers of Excellence already established throughout the country. Among them, Prof. Antonino Agrusa from the University of Palermo leads the surgical team at the Policlinico. He enthusiastically reports, "Almost a year after the procedure, our patients exhibit exceptional outcomes—no reflux and improved swallowing abilities. This signifies a remarkable shift for patients across Sicily."
Dr. Günther Sitzmann, Chief of General Surgery at Ospedale di Brunico, echoes this sentiment by stating, "RefluxStop® enables patients to reclaim activities they had forsaken due to GERD. Providing them with a solution is incredibly fulfilling."
The successful implementation of RefluxStop® has been bolstered by ongoing governmental recognition of its efficacy and the transformative impact it holds for patients who previously faced limited treatment options. Dr. Peter Forsell, CEO of Implantica and the device's inventor, emphasizes the importance of this recognition. He notes, "Acknowledgment from healthcare authorities is essential for patients who deserve optimal care. We are immensely grateful to Prof. Agrusa and Dr. Sitzmann for their dedication to enhancing GERD patients' access to superior treatment. Securing these public tenders is vital for broader acceptance and establishing long-term reimbursement pathways."
The urgency to address GERD is underscored by its prevalence, with estimates suggesting that more than 12 million adults in Italy alone suffer from this condition. The advancements brought forth by RefluxStop® not only serve the local population but also have implications for millions of individuals worldwide looking for relief from this debilitating ailment.
As the healthcare community evolves to meet the demands of patients, innovations such as RefluxStop® illuminate a promising path forward. By embedding cutting-edge technology into medical treatments, Implantica champions a future where patients no longer need to live with the discomfort of acid reflux. With this latest funding, the company's ongoing commitment to revolutionize the GERD treatment landscape is set to gain momentum, paving the way for better health outcomes across Europe and beyond.
The funding was awarded through two multi-year public tender approvals at esteemed healthcare institutions: Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" in Palermo and the Ospedale di Brunico, part of the Azienda Sanitaria dell'Alto Adige in South Tyrol. This accomplishment marks a critical juncture for RefluxStop®, indicating its growing acceptance and recognition within Italy's national healthcare framework.
The RefluxStop® device is uniquely engineered to address the root causes of acid reflux without imposing pressure on the esophagus, unlike traditional surgical methods. Its innovative mechanism restores the natural position and function of the lower esophageal sphincter, which plays a crucial role in preventing acid from escaping the stomach. This is achieved without the encirclement and potential side effects associated with conventional reflux surgeries.
Italy is witnessing an uptick in the clinical deployment of this revolutionary treatment, with twelve Centers of Excellence already established throughout the country. Among them, Prof. Antonino Agrusa from the University of Palermo leads the surgical team at the Policlinico. He enthusiastically reports, "Almost a year after the procedure, our patients exhibit exceptional outcomes—no reflux and improved swallowing abilities. This signifies a remarkable shift for patients across Sicily."
Dr. Günther Sitzmann, Chief of General Surgery at Ospedale di Brunico, echoes this sentiment by stating, "RefluxStop® enables patients to reclaim activities they had forsaken due to GERD. Providing them with a solution is incredibly fulfilling."
The successful implementation of RefluxStop® has been bolstered by ongoing governmental recognition of its efficacy and the transformative impact it holds for patients who previously faced limited treatment options. Dr. Peter Forsell, CEO of Implantica and the device's inventor, emphasizes the importance of this recognition. He notes, "Acknowledgment from healthcare authorities is essential for patients who deserve optimal care. We are immensely grateful to Prof. Agrusa and Dr. Sitzmann for their dedication to enhancing GERD patients' access to superior treatment. Securing these public tenders is vital for broader acceptance and establishing long-term reimbursement pathways."
The urgency to address GERD is underscored by its prevalence, with estimates suggesting that more than 12 million adults in Italy alone suffer from this condition. The advancements brought forth by RefluxStop® not only serve the local population but also have implications for millions of individuals worldwide looking for relief from this debilitating ailment.
As the healthcare community evolves to meet the demands of patients, innovations such as RefluxStop® illuminate a promising path forward. By embedding cutting-edge technology into medical treatments, Implantica champions a future where patients no longer need to live with the discomfort of acid reflux. With this latest funding, the company's ongoing commitment to revolutionize the GERD treatment landscape is set to gain momentum, paving the way for better health outcomes across Europe and beyond.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.